{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:58:56Z","timestamp":1786687136924,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cgh.2022.02.013","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:10:20Z","timestamp":1644970220000},"page":"2485-2494.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1167-1101","authenticated-orcid":false,"given":"Evan S.","family":"Dellon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo J.","family":"Lucendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain M.","family":"Schoepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Eagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nezamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail M.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Knoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.02.013_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mcna.2018.08.009","article-title":"Eosinophilic esophagitis","volume":"103","author":"Reed","year":"2019","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.cgh.2022.02.013_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.013_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2022.02.013_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE Conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0016-5107(05)00313-5","article-title":"Association of eosinophilic inflammation with esophageal food impaction in adults","volume":"61","author":"Desai","year":"2005","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2022.02.013_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14072","article-title":"Emerging incidence trends of eosinophilic esophagitis over 25 years: results of a nationwide register-based pathology cohort","volume":"33","author":"Rooij","year":"2021","journal-title":"Neurogastroenter Motil"},{"key":"10.1016\/j.cgh.2022.02.013_bib8","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/apt.15231","article-title":"Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies","volume":"49","author":"Navarro","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.02.013_bib9","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1053\/j.gastro.2014.02.006","article-title":"Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis","volume":"146","author":"Arias","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib10","series-title":"Jorveza (Budesonide) Orally Disintegrating Tablet","year":"2021"},{"key":"10.1016\/j.cgh.2022.02.013_bib11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cgh.2017.03.016","article-title":"AGA White Paper: drug development for eosinophilic esophagitis","volume":"15","author":"Hirano","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib12","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.3748\/wjg.v26.i36.5395","article-title":"Treatment of eosinophlic esophagitis with swallowed topical corticosteroids","volume":"26","author":"Nennstiel","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.013_bib13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib14","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/j.1572-0241.2008.01989.x","article-title":"3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults","volume":"103","author":"Helou","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.013_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2011.01.017","article-title":"Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis","volume":"9","author":"Straumann","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2019.08.050","article-title":"Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial","volume":"18","author":"Dellon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cgh.2007.11.008","article-title":"Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children","volume":"6","author":"Schaefer","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.14573","article-title":"Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis","volume":"47","author":"Philpott","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.02.013_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.02.013_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(20)32724-4","article-title":"An episode-based, patient-reported outcome measure of dysphagia experience is feasible and not burdensome for patients with eosinophilic esophagitis","volume":"158","author":"Dellon","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","article-title":"International Eosinophilic Esophagitis Activity Index Study Group. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis","volume":"147","author":"Schoepfer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.anai.2020.03.020","article-title":"AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"124","author":"Hirano","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.cgh.2022.02.013_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.anai.2020.03.021","article-title":"Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters","volume":"124","author":"Rank","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.cgh.2022.02.013_bib24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"MP-101-06 Investigators. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.02.013_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17474124.2020.1785869","article-title":"Recent insights on the use of topical steroids in eosinophilic esophagitis","volume":"14","author":"Reddy","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib31","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2014.07.034","article-title":"Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients","volume":"13","author":"Wolf","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.02.013_bib32","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.gie.2015.11.019","article-title":"The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis","author":"Eluri","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2022.02.013_bib33","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.14309\/00000434-201310001-00037","article-title":"Predictors of non-response to topical steroids treatment in eosinophilic esophagitis","author":"Moawad","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2022.02.013_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(08)80004-2","article-title":"The human pharmacology of fluticasone propionate","author":"Harding","year":"1990","journal-title":"Respir Med"},{"key":"10.1016\/j.cgh.2022.02.013_bib35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/jcph.1572","article-title":"Effect of food intake and body position on the pharmacokinetics of swallowed APT-1011, a fluticasone orally disintegrating tablet, in healthy adult volunteers","volume":"60","author":"Comer","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2022.02.013_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"all ORBIT1\/SHP621-301 Investigators. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:39:54Z","timestamp":1761543594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1542356522001392"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.02.013","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}